Abstract:Introduction: Major histocompatibility complex (MHC) genes are an integral part of the adaptive immune system. The T-cells can detect and kill cancer cells through the recognition of mutant peptides on the cell surface via the MHC. As a result, many cancers evade the immune system by altering their MHC regulation which can also lead to resistance to immune checkpoint blockade (ICB). Therefore, understanding MHC regulation in both baseline (normal state) and cancer is critical for uncovering mechanisms behind MHC alterations. Here, we have undertaken a pan-tissue evaluation to comprehensively decode MHC transcriptional regulation in healthy tissues and various cancers using a large compendium of single-cell RNA-seq (scRNA-seq) datasets. Methods: To study MHC class I (MHC-I) and MHC class II (MHC-II) transcriptional regulation at baseline we leveraged a large-scale scRNA-seq dataset encompassing 18 tissues and 124 epithelial cell types. Upon re-clustering and annotation, we investigated MHC expression across cell types and tissues and quantified its heterogeneity using the Gini coefficient. Next, we sought to identify transcription factors (TF) predictive of MHC-I and MHC-II expression, for that, we employed a master regulator inference that utilizes uni- and multi- regression models. Further, to investigate MHC and nominated TFs dysregulation in cancer, we curated a compendium of scRNA-seq datasets comprising 43 datasets, 20 cancer types, across 538 patients. Results: In normal epithelial cell types, we observed a large range (~8 fold) in MHC-I expression. We also detected MHC-II expression in unexpected cell types such as club cells in the prostate. We found that lung epithelial cells showed elevated MHC-II expression. Immunohistochemistry was performed to validate these findings. Using master regulator inference, we nominated 104 and 107 TFs which predict MHC-I and MHC-II expression, respectively. The nominated TFs showed significant enrichment (p < 0.001) for known TFs, alongside putative novel transcriptional regulators such as YBX1 (MHC-I p < 2e-16, MHC-II p = 8e-07) and XBP1 (MHC-I p < 2e-16, MHC-II p = 7e-04). Using our single-cell compendium of 20 cancer types we also observed a pan-cancer repression in MHC genes (p < 0.001). Next, we utilized an ICB cohort to identify specific TFs that could predict therapeutic benefits. Interestingly, XBP1 (p < 1e-16) and SP100 (p < 2.2e-08) were strong predictors of patients' survival. We also observed a large heterogeneity in MHC-II expression among colon cancer patients. Upon investigation, we found that patients with high MHC-II expression were mismatch repair deficient, this implicates MHC-II upregulation as an immune evasion mechanism. Conclusion: In conclusion, we have comprehensively evaluated MHC expression in 124 epithelial cell types and across 20 cancers identifying TFs predictive of MHC-I and MHC-II expression and their effects on patient outcomes. Citation Format: Mahnoor N. Gondal, Rahul Mannan, Yi Bao, Jing Hu, Marcin Cieslik, Arul M. Chinnaiyan. Pan-tissue master regulator inference reveals mechanisms of MHC alterations in cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 860.

Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy

Unveiling Major Histocompatibility Complex-mediated Pan-Cancer Immune Features by Integrated Single-Cell and Bulk RNA Sequencing

Patient HLA Class I Genotype Influences Cancer Response to Checkpoint Blockade Immunotherapy

Integrative HLA typing of tumor and adjacent normal tissue can reveal insights into the tumor immune response

Assessment of Human Leukocyte Antigen-Based Neoantigen Presentation to Determine Pan-Cancer Response to Immunotherapy

Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects.

Integrative analysis of single-cell and bulk RNA sequencing unveils a machine learning-based pan-cancer major histocompatibility complex-related signature for predicting immunotherapy efficacy

Targeting MHC-I Molecules for Cancer: Function, Mechanism, and Therapeutic Prospects

Co-expression of HLA-I loci improved prognostication in HER2+ breast cancers

Human Leukocyte Antigen and Tumor Immunotherapy (Review)

Proteogenomics Reveal the Overexpression of HLA-I in Cancer

Systematic analysis the genomic and microenvironment characteristics with the status of human leukocyte antigen (HLA) and the integration of HLA LOH, TMB and PD-L1 could further distinguish the responders to immunotherapy.

Germline HLA-B Evolutionary Divergence to Influence Efficacy of Immune Checkpoint Blockade Therapy in Gastrointestinal Cancer.

Harnessing the potential of HLA-G in cancer therapy: advances, challenges, and prospects

Germline HLA-B Evolutionary Divergence Influences the Efficacy of Immune Checkpoint Blockade Therapy in Gastrointestinal Cancer

Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma

The HLA-I landscape confers prognosis and antitumor immunity in breast cancer

Human Leucocyte Antigens as Prognostic Markers in Head and Neck Squamous Cell Carcinoma

Abstract 860: Pan-tissue master regulator inference reveals mechanisms of MHC alterations in cancers

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma

An integrated database of experimentally validated major histocompatibility complex epitopes for antigen-specific cancer therapy